

# Michael Fuchs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8755350/publications.pdf>

Version: 2024-02-01

34  
papers

1,830  
citations

623188

14  
h-index

433756

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1699  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 363, 640-652.	13.9	824
2	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. <i>Lancet, The</i> , 2015, 385, 1418-1427.	6.3	154
3	Positron Emission Tomographyâ€“Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2835-2845.	0.8	151
4	Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma. <i>JAMA Oncology</i> , 2020, 6, 872.	3.4	112
5	Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 1999-2007.	0.8	108
6	Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. <i>Lancet Oncology, The</i> , 2016, 17, 1453-1462.	5.1	91
7	Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. <i>Journal of Clinical Oncology</i> , 2016, 34, 4329-4337.	0.8	70
8	Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. <i>Blood</i> , 2020, 136, 2851-2863.	0.6	47
9	Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 1444-1450.	0.8	32
10	Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 2839-2848.	0.8	28
11	PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology,the</i> , 2021, 8, e398-e409.	2.2	28
12	Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3528-3537.	0.8	26
13	CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5826.	1.8	22
14	Early Response to First-Line Antiâ€“PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial. <i>Clinical Cancer Research</i> , 2021, 27, 402-407.	3.2	20
15	Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. <i>Leukemia</i> , 2020, 34, 953-956.	3.3	14
16	Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG) Tj ETQq0 0 0 rg2T/Overlo1k 10 Tf 50		
17	Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group. <i>Leukemia</i> , 2022, 36, 580-582.	3.3	12
18	Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial. <i>Blood</i> , 2019, 134, 1547-1547.	0.6	10

#	ARTICLE	IF	CITATIONS
19	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. <i>British Journal of Haematology</i> , 2022, 196, 116-126.	1.2	9
20	Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. <i>Blood</i> , 2008, 112, 367-367.	0.6	9
21	Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 2603-2611.	0.8	7
22	Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. <i>Leukemia</i> , 2022, 36, 772-780.	3.3	6
23	Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. <i>Hematological Oncology</i> , 2022, 40, 801-804.	0.8	6
24	Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 107-115.	0.8	5
25	Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group. <i>British Journal of Haematology</i> , 2021, 193, 515-519.	1.2	5
26	Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis. <i>British Journal of Haematology</i> , 2022, 198, 401-404.	1.2	5
27	Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 900-906.	0.4	4
28	Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group. <i>British Journal of Haematology</i> , 2021, , .	1.2	4
29	Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabine and cisplatin in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD3i). <i>British Journal of Haematology</i> , 2022, 196, 606-616.	1.2	4
30	Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Large Multi-Trial Analysis Based on Individual Patient Data. <i>Blood</i> , 2021, 138, 879-879.	0.6	3
31	Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3324-3325.	0.8	2
32	Reply to H.J.A. Adams et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1116-1117.	0.8	0
33	Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma. <i>Infection</i> , 2022, , 1.	2.3	0
34	Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2022, 197, .	1.2	0